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Abstract: Background: Hemp (Cannabis sativa L.) seed contains high contents of various nutrients,
including fatty acids and proteins. Cannabidiol (CBD) is a non-psychoactive compound that can
be extracted from C. sativa and used for treating epilepsy and pain. Industrial hemp products,
including CBD and hemp seed oils, have become increasingly popular. Some products are marketed
without a clear distinction between CBD and hemp seed oils. Herein, the CBD content and
biological activities of commercial CBD and hemp seed oils were examined. Methods: CBD
content was measured by high-performance liquid chromatography. For in vitro antioxidant activity
determination, 2,2-diphenyl-1-picrylhydrazyl and 2,2′-azinobis (3-ethylbenzothiazoline-6-sulfonic
acid) radical-scavenging assays were performed. Results: The CBD concentrations in the two CBD
oil samples were 18.9 ± 0.5 and 9.2 ± 0.4 mg/mL. Of the seven hemp seed oil samples, six samples
contained CBD in concentrations ranging from 2.0 ± 0.1 to 20.5 ± 0.5 µg/mL, but it was not detected
in one sample. Antioxidant activity was observed in both CBD oil samples. Conclusions: The results
indicate that (1) CBD content varied by hemp seed oil sample and that (2) antioxidant activity could
be a useful landmark for discriminating CBD oils from hemp seed oils.
Keywords: Cannabidiol; hemp; antioxidant; Cannabis sativa
1. Introduction
Cannabis sativa L. has been cultivated worldwide for centuries for medicinal, industrial and
recreational use. The characteristic compounds of C. sativa L. are cannabinoids, including delta-9
tetrahydrocannabinol (THC) and cannabidiol (CBD) [1]. THC is the main psychoactive compound,
whereas CBD is non-psychoactive and can effectively treat epilepsy and other neuropsychiatric
disorders [2–8]. Therefore, an increasing number of CBD products have been marketed worldwide.
Commercial CBD products are primarily produced from industrial C. sativa or hemp, which contains
little or no THC [9,10]. Hemp seed is often utilized as a functional food and medicine. In Kampo
medicine, it is known as Mashinin, and is used as a laxative [11]. Hemp seed oil contains >80%
polyunsaturated fatty acids with two essential fatty acids, i.e., linoleic acid (18:2 omega-6) and
alpha-linolenic acid (18:3 omega-3) [12]. The omega-6 to omega-3 ratio in hemp seed oil is considered to
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be nutritionally optimal [9,10,12]. Some reports have demonstrated that cannabinoids can be detected
in commercial hemp seed products [12,13]. Considering that hemp seed produces no cannabinoids in
its metabolic pathways, it could be contaminated with resin from the flowers and leaves, which contain
cannabinoids, during hemp seed processing [12–14].
Few reports have been published on the CBD quantification of CBD oil products marketed in
Japan, or on the existence of CBD in hemp seed oils commercially available in Japan. In addition,
some products are marketed without a clear distinction between CBD and hemp seed oils. Essential
oil obtained from hemp is commonly studied using a multidisciplinary approach for evaluating
various biological activities, including antioxidant capacity, enzyme inhibition, antimicrobial activity
and cytotoxicity on cell lines [15–17]. CBD has demonstrated strong antioxidant effects and can be
considered a potent neuroprotective agent [8,18]. Therefore, in vitro biological assays might be useful
for discriminating CBD oils from hemp seed oils. Herein, commercially available CBD and hemp seed
oil products were analyzed using high-performance liquid chromatography (HPLC). Additionally,
their antioxidant activities were determined.
2. Materials and Methods
2.1. Samples
CBD, hemp seed and rapeseed oils were purchased online as described in Table 1.
Table 1. CBD and hemp seed oil samples in this study.
Sample Product Product Origin
C1 CBD oil USA
C2 CBD oil Unknown
C3 Hemp seed oil Australia
C4 Hemp seed oil New Zealand
C5 Hemp seed oil Unknown
C6 Hemp seed oil Germany
C7 Hemp seed oil Germany
C8 Hemp seed oil Canada
C9 Rapeseed oil Japan
2.2. HPLC Analysis
HPLC analyses were performed using an Alliance Waters e2695 (Waters) and Alliance Waters
2998 PDA detector. An XTerra MS C18 column (3.5 µm, 4.6 mm × 150 mm, Waters) was used with an
isocratic mobile phase of water (0.1% formic acid): acetonitrile 3:7 at a flow rate of 0.8 mL/min for 30 min.
The column temperature was set to 35 ◦C and sample injection volume was 10 µL. The chromatograms
were monitored at 235 nm. The HPLC analysis for CBD detection and validation was based on
previously reported methods with modification [12,19]. CBD and THC reference standards were
obtained from Cayman Chemical, Michigan, USA and Sigma-Aldrich, USA, respectively. Standard
stock solutions of CBD (100 µg/mL) were prepared in methanol, and calibration curves were prepared
with the CBD standard at concentrations of 100, 50, 25, 12.5, 5 and 0.5 µg/mL (Figure S1). Linearity was
assessed by evaluating the coefficient of determination (R2). HPLC chromatographs of CBD and THC
standards are shown in Supplementary Materials. The instrumental limit of detection (LOD) values
were calculated using the following formula: LOD = (3.3 × σ)/m, where σ is the residual standard
deviation of the calibration curve and m is the calibration curve slope. The limit of quantification
(LOQ) values were determined according to the following formula: LOQ = (10 × σ)/m. The intra-day
repeatability of the method was assessed by analyzing three replicates of the samples injected thrice on
the same day. The relative standard deviation (RSD) of the three replicates was also calculated.
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2.3. Sample Preparation for HPLC
CBD oils were diluted with methanol and injected into the HPLC system. First, 5 mL of hemp
seed oil was extracted with 20 mL methanol. After solvent evaporation, the samples were heated at
100 ◦C for 2 h. Subsequently, the samples were added to methanol and injected into the HPLC system.
All the analyses were performed in triplicate, and the data are expressed as mean ± standard deviation.
2.4. Antioxidant Assay
2,2-Diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-azinobis (3-ethylbenzothiazoline-6-sulfonic acid)
(ABTS) radical-scavenging assays were performed. The oils (250 µL) were extracted with 1 mL
methanol for 10 min with occasional shaking. After incubation, the supernatant was used as the
sample solution. The DPPH assay was performed according to a previously described protocol [20,21].
In a total volume of 200 µL, 180 µL of 100 µM DPPH dissolved in methanol and 20 µL of the samples
dissolved in methanol were incubated for 30 min at room temperature. The absorbance of the mixture
was measured at 517 nm using a microplate reader (Molecular Devices SPECTRA MAX M2). The ABTS
radical-scavenging activity was determined according to a previously described assay with some
minor modifications [21]. Briefly, 7 mM ABTS in H2O and 2.45 mM potassium persulfate were mixed
in a 1:1 ratio. Then, the solution was diluted in methanol at a 1:25 ratio. In a 96-well plate, 180 µL
of the diluted solution and 20 µL of each sample dissolved in methanol were mixed and incubated
for 10 min at room temperature, and absorbance was measured at 734 nm. The percentage enzyme
activity inhibition was calculated by comparison with the negative control: Inhibition (%) = 100 × (A0
− A1)/A0, where A0 is the negative control absorbance and A1 is the sample absorbance. For each
sample with a percentage inhibition of >60%, the IC50 values were determined from a dose–response
curve with eight different concentrations. Ascorbic acid was used as a positive control.
3. Results
3.1. HPLC Analysis of CBD and Hemp Seed Oils
Herein, two CBD and seven hemp seed oil samples were evaluated, while rapeseed oil was used
as a CBD-free sample. To quantify the CBD concentration of CBD and hemp seed oils, HPLC analysis
was performed. A calibration curve was constructed using CBD standards (100, 50, 25, 12.5, 5 and
0.5 µg/mL). The linearity plot and chromatograph are shown in the Supplementary Materials, and the
linearity coefficient of determination (R2) was 0.995. From Table 2, the LOD, LOQ, as well as intra- and
inter-day RSD were 1.5 µg/mL, 4.6 µg/mL, 4.2% and 2.4%, respectively.
Table 2. Parameters for method validation.
Factors Results
Equation y = 18600x − 23348
R2 0.995
LOD (µg/mL) 1.5
LOQ (µg/mL) 4.6
RSD (Intra-Day) 4.2%
RSD (Inter-Day) 2.4%
Using the HPLC method, CBD and hemp seed oil samples were analyzed. Because CBD exists
primarily in the carboxylated form, cannabidiol acid (CBDA), in fresh C. sativa L. plants, hemp seed oil
samples were heated at 100 ◦C for 2 h to decarboxylate CBDA into CBD [12]. The CBD concentration
of each sample is shown in Figure 1. The CBD oil samples (C1 and C2) showed concentrations of
18.9 ± 0.5 and 9.2 ± 0.4 mg/mL, respectively, which were nearly equal to the value displayed on the
product description (500 mg/30 mL and 300 mg/30 mL, respectively). Of the seven hemp oil samples
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tested, six contained CBD concentrations ranging from 2.0 ± 0.1 (C6) to 20.5 ± 0.5 (C4) µg/mL, and
CBD was not detected in one hemp seed oil sample (C7) or rape oil sample (C9).Medicines 2020, 7, x FOR PEER REVIEW 4 of 6 
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3.2. Biological Activities of CBD and Hemp Seed Oils
To assess the biological activities of CBD and hemp seed oils in vitro, ABTS and DPPH assays
were performed (Table 3). The DPPH and ABTS assay results indicated that antioxidant activities in
the CBD oil samples were higher than those in the hemp seed oil samples. The CBD oil samples (C1
and C2) showed dose–response DPPH scavenging activities with IC50 values of 17.9 and 18.6 µL/mL,
respectively. The CBD oil samples (C1 and C2) also showed dose–response ABTS scavenging activities
with IC50 values of 2.3 and 3.6 µL/mL, respectively. To confirm the antioxidant activity of the CBD oil
samples, the DPPH and ABTS scavenging activities were evaluated using a CBD standard. The IC50
values of the CBD standard in the DPPH and ABTS assays were 584 and 92.2 µM, respectively. The IC50
values of the CBD oil samples (C1 and C2) calculated using each concentration obtained from Figure 1
were respectively 1075 and 522 µM in the DPPH assay, and 138 and 67 µM in the ABTS assay. These
results indicated that the antioxidant potential of CBD oil could be attributed to CBD.
Table 3. Biological activities of CBD and hemp seed oils.
Sample
Antioxidant Activity
DPPH ABTS
Sample Conc.
(25 µL/mL)
IC50
(CBD)
Sample Conc.
(25 µL/mL)
IC50
(CBD)
C1 64.8 ± 0.8% 17.9 µL/mL(1075 µM) 90.5 ± 0.1%
2.3 µL/mL
(138 µM)
C2 63.2 ± 1.4% 18.6 µL/mL(522 µM) 90.3 ± 0.1%
3.6 µL/mL
(67 µM)
C3 12.7 ± 0.8% - 28.2 ± 2.4% -
C4 23.2 ± 1.0% - 47.8 ± 2.0% -
C5 19.8 ± 0.4% - 21.8 ± 1.3% -
C6 11.1 ± 0.6% - 27.3 ± 1.1% -
C7 1.3 ± 0.8% - 2.8 ± 1.2% -
C8 11.6 ± 1.1% - 26.9 ± 1.0% -
C9 14.5 ± 0.6% - 36.6 ± 1.9% -
Ascorbic
Acid - 38.0 µM - 11.3 µM
CBD - 584 µM - 92.2 µM
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4. Discussion
Herein, it was found that six of seven hemp seed oil products contained CBD, while the
concentration varied by sample. Therefore, the unintended intake of CBD from hemp seed oil products
might occur. Considering the adverse effects of CBD, including developmental toxicity, embryo-fatal
mortality and neurotoxicity, unintended consumption of CBD should be avoided [22]. The cannabinoid
content in hemp seed oil products could be affected by strain, product origin and processing steps.
In this study, THC was not detected in any samples. Previous reports showed that some hemp seed oil
products contained cannabinoids, including CBD and THC [10,12]. In Japan, CBD and hemp seed
oil products containing THC are strictly prohibited by law. In addition, some products are marketed
without a clear distinction between CBD and hemp seed oils. Therefore, the quality control of CBD
and hemp seed oil products is necessary. In the antioxidant assays, the CBD oils exhibited free radical
scavenging activities in a CBD dose-dependent manner. Because the DPPH and ABTS assays are
simple and rapid, antioxidant activity represents a useful marker for distinguishing between CBD
and hemp seed oils. Previously, the antioxidant activities of cannabinoids and C. sativa extracts were
evaluated by DPPH and ABTS assays [18]. CBD and THC showed similar antioxidant activities by
ABTS assay, whereas the antioxidant activity of CBD determined by DPPH assay was two-fold higher
than that of THC [18]. Therefore, the ratio of antioxidant activity determined by DPPH assay to that by
ABTS assay might be useful information for the quality control of CBD oils to avoid contamination
with THC.
5. Conclusions
In this study, we analyzed the CBD contents and antioxidant activities of CBD and hemp seed
oils commercially available in Japan. The CBD contents of hemp seed oils varied by sample. Because
CBD oil samples exhibited strong antioxidant activities, antioxidant assays represent a useful marker
for distinguishing between CBD and hemp seed oils. Our results could be applicable for the quality
control of CBD and hemp seed oil products.
Supplementary Materials: The following are available online at http://www.mdpi.com/2305-6320/7/9/57/s1,
Figure S1: (a) Linearity plot of CBD standard. (b) HPLC chromatographs of CBD standard, THC standard, and
CBD oil sample (C1).
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10. Petrović, M.; Debeljak, Ž.; Kezić, N.; Džidara, P. Relationship between Cannabinoids Content and Composition
of Fatty Acids in Hempseed Oils. Food Chem. 2015, 170, 218–225. [CrossRef]
11. Iwasaki, K.; Takayama, S. Hemp Seed Pill May Improve Chronic Constipation of the Elderly and Reduce the
Burden of Helpers. J. Fam. Med. Prim. Care 2019, 8, 2150. [CrossRef] [PubMed]
12. Citti, C.; Pacchetti, B.; Vandelli, M.A.; Forni, F.; Cannazza, G. Analysis of Cannabinoids in Commercial Hemp
Seed Oil and Decarboxylation Kinetics Studies of Cannabidiolic Acid (CBDA). J. Pharm. Biomed. Anal. 2018,
149, 532–540. [CrossRef] [PubMed]
13. Matsunaga, T.; Watanabe, K.; Yoshimura, H.; Yamamoto, I. Quantitative Analysis and Pharmaco-Toxicity of
Cannabinoids in Commercially Available Cannabis Seeds. Yakugaku Zasshi 1998, 118, 408–414. [CrossRef]
[PubMed]
14. Russo, E.B.; Marcu, J. Cannabis Pharmacology: The Usual Suspects and a Few Promising Leads.
Adv. Pharmacol. 2017, 80, 67–134.
15. Yan, X.; Tang, J.; Dos Santos Passos, C.; Nurisso, A.; Simoes-Pires, C.A.; Ji, M.; Lou, H.; Fan, P. Characterization
of Lignanamides from Hemp (Cannabis Sativa L.) Seed and Their Antioxidant and Acetylcholinesterase
Inhibitory Activities. J. Agric. Food Chem. 2015, 63, 10611–10619. [CrossRef]
16. Nissen, L.; Zatta, A.; Stefanini, I.; Grandi, S.; Sgorbati, B.; Biavati, B.; Monti, A. Characterization and
Antimicrobial Activity of Essential Oils of Industrial Hemp Varieties (Cannabis Sativa L.). Fitoterapia 2010, 81,
413–419. [CrossRef]
17. Zengin, G.; Menghini, L.; Di Sotto, A.; Mancinelli, R.; Sisto, F.; Carradori, S.; Cesa, S.; Fraschetti, C.; Filippi, A.;
Angiolella, L.; et al. Chromatographic Analyses, In Vitro Biological Activities, and Cytotoxicity of Cannabis
Sativa L. Essential Oil: A Multidisciplinary Study. Molecules 2018, 23, 3266. [CrossRef]
18. Hacke, A.C.M.; Lima, D.; de Costa, F.; Deshmukh, K.; Li, N.; Chow, A.M.; Marques, J.A.; Pereira, R.P.;
Kerman, K. Probing the antioxidant activity of ∆9-tetrahydrocannabinol and cannabidiol in Cannabis sativa
extracts. Analyst 2019, 144, 4952–4961. [CrossRef]
19. Mandrioli, M.; Tura, M.; Scotti, S.; Toschi, G.T. Fast Detection of 10 Cannabinoids by RP-HPLC-UV Method
in Cannabis sativa L. Molecules 2019, 24, 2113. [CrossRef]
20. Takao, K.; Toda, K.; Saito, T.; Sugita, Y. Synthesis of Amide and Ester Derivatives of Cinnamic Acid and
Its Analogs: Evaluation of Their Free Radical Scavenging and Monoamine Oxidase and Cholinesterase
Inhibitory Activities. Chem. Pharm. Bull. 2017, 65, 1020–1027. [CrossRef]
21. Atolani, O.; Oguntoye, H.; Areh, E.T.; Adeyemi, O.S.; Kambizi, L. Chemical Composition, Anti-Toxoplasma,
Cytotoxicity, Antioxidant, and Anti-Inflammatory Potentials of Cola Gigantea Seed Oil. Pharm. Biol. 2019, 57,
154–160. [CrossRef] [PubMed]
22. Huestis, M.A.; Solimini, R.; Pichini, S.; Pacifici, R.; Carlier, J.; Busardò, F.P. Cannabidiol Adverse Effects and
Toxicity. Curr. Neuropharmacol. 2019, 17, 974–989. [CrossRef] [PubMed]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
